Compare · NVO vs RNXT
NVO vs RNXT
Side-by-side comparison of Novo Nordisk A/S (NVO) and RenovoRx Inc. (RNXT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and RNXT operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $215.46B, about 3362.2x RNXT ($64.1M).
- RNXT has been more active in the news (12 items in the past 4 weeks vs 9 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 2 for RNXT).
- Company
- Novo Nordisk A/S
- RenovoRx Inc.
- Price
- -
- -
- Market cap
- $215.46B
- $64.1M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2021
- News (4w)
- 9
- 12
- Recent ratings
- 25
- 2
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- SEC Form 6-K filed by Novo Nordisk A/S
- Novo Nordisk A/S downgraded by Berenberg
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
Latest RNXT
- RenovoRx Highlights Peer-Reviewed Publication of Pharmacokinetic and Pharmacodynamic (PK/PD) Data Supporting TAMP™ Platform’s Targeted Drug-Delivery in Locally Advanced Pancreatic Cancer
- RenovoRx Regains Compliance with Nasdaq Minimum Bid Price Requirement
- RenovoRx Inc. filed SEC Form 8-K: Other Events
- RenovoRx Receives Notice of Allowance for New U.S. Patent Covering RenovoCath®, an Advanced Dual-Occlusion Catheter, for Targeted Therapeutic Drug-Delivery for Cancer Treatment
- SEC Form 10-Q filed by RenovoRx Inc.
- Amendment: RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RenovoRx Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- RenovoRx Reports Record Second Quarter 2026 Results, Driven by Accelerating Commercial Adoption and 61% Sequential Quarterly Revenue Growth
- RenovoRx Achieves Major Milestone with Full Enrollment in Phase III TIGeR-PaC Trial for Locally Advanced Pancreatic Cancer
- RenovoRx Announces First Commercial Clinical Use of RenovoCath® in Sarcoma Patient Treatment, Marking Expansion of Targeted Drug-Delivery Device to Other Solid Tumors